SOPHIA ANTIPOLIS CEDEX, FRANCE--(Marketwired - May 03, 2013) -
Nicox attends 2013 congress of the French Society of Ophthalmology (SFO) in
May 3, 2013.
Sophia Antipolis, France.
Nicox S.A. (EURONEXT PARIS: COX) is attending for the first time the
119(th) congress of the French Society of Ophthalmology (SFO) taking place
from May 11 to 14, 2013 in Paris, France. Nicox can be found at booth
Nicox's European and International Operations team, including Philippe
Masquida, Vice President and Managing Director of European and
International Operations of Nicox Pharma will present AdenoPlus®, a
rapid point-of-care diagnostic test that aids in the differential diagnosis
of acute conjunctivitis.
Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is creating a new mid-sized
international player in the ophthalmic market by building a diversified
portfolio of innovative therapies and diagnostic tools. With a heritage of
scientific, business development and commercial expertise, the Nicox team
is focused on developing and marketing novel pharmaceuticals and diagnostic
devices that can help people to enhance their sight. In the United States,
Nicox markets AdenoPlus®, a test for the differential diagnosis of
acute conjunctivitis in-licensed from RPS®.
The Company's pipeline includes latanoprostene bunod, a novel drug-
candidate based on Nicox's proprietary nitric oxide (NO)-donating R&D
platform, developed in collaboration with Bausch + Lomb for the potential
treatment of glaucoma and ocular hypertension. Further NO-donating
compounds are under development in non- ophthalmic indications, notably
through partners, including Merck (known as MSD outside the United States
Nicox S.A. is headquartered in France and is listed on Euronext
Paris (Compartment B: Small Caps). For more information please visit
This communication may contain certain forward-looking statements. Although
the Company believes its expectations are based on reasonable assumptions,
these forward-looking statements are subject to numerous risks and
uncertainties, which could cause actual results to differ materially from
those anticipated in the forward-looking statements.
Risks factors which are likely to have a material effect on Nicox's
business are presented in the 4th chapter of the « Document de
référence, rapport financier annuel et rapport de gestion 2012
» filed with the French Autorité des Marchés Financiers
(AMF) on March 22, 2013 and available on Nicox's website (www.nicox.com)
and on the AMF's website (www.amf-france.org).
Nicox attends 2013 congress of the French Society of Ophthalmology (SF:
This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: NICOX via Thomson Reuters ONE